ATE381017T1 - Kathepsin y inhibitoren für die entwicklung von medikamenten zur schmerzbehandlung - Google Patents

Kathepsin y inhibitoren für die entwicklung von medikamenten zur schmerzbehandlung

Info

Publication number
ATE381017T1
ATE381017T1 AT02003400T AT02003400T ATE381017T1 AT E381017 T1 ATE381017 T1 AT E381017T1 AT 02003400 T AT02003400 T AT 02003400T AT 02003400 T AT02003400 T AT 02003400T AT E381017 T1 ATE381017 T1 AT E381017T1
Authority
AT
Austria
Prior art keywords
cathepsin
development
inhibitors
pain treatment
treatment medications
Prior art date
Application number
AT02003400T
Other languages
English (en)
Inventor
Hermann Luebbert
Beate Schmitz
Original Assignee
Biofrontera Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofrontera Pharmaceuticals Ag filed Critical Biofrontera Pharmaceuticals Ag
Application granted granted Critical
Publication of ATE381017T1 publication Critical patent/ATE381017T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02003400T 2002-02-14 2002-02-14 Kathepsin y inhibitoren für die entwicklung von medikamenten zur schmerzbehandlung ATE381017T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02003400A EP1336847B1 (de) 2002-02-14 2002-02-14 Kathepsin Y Inhibitoren für die Entwicklung von Medikamenten zur Schmerzbehandlung

Publications (1)

Publication Number Publication Date
ATE381017T1 true ATE381017T1 (de) 2007-12-15

Family

ID=27619135

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02003400T ATE381017T1 (de) 2002-02-14 2002-02-14 Kathepsin y inhibitoren für die entwicklung von medikamenten zur schmerzbehandlung

Country Status (4)

Country Link
EP (1) EP1336847B1 (de)
AT (1) ATE381017T1 (de)
DE (1) DE60224002T2 (de)
ES (1) ES2296834T3 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003210347A1 (en) * 2003-02-25 2004-09-17 Biofrontera Pharmaceuticals Gmbh Cathepsin y for the treatment of pain
US20070155650A1 (en) * 2003-12-30 2007-07-05 Aventis Pharmaceuticals Inc. Use of cathepsin z inhibitors for the treatment of rhuematoid arthritis and other autoimmune diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11506923A (ja) * 1995-06-06 1999-06-22 アセナ ニューロサイエンシーズ，インコーポレイテッド 新しいカテプシンならびにその阻害のための方法および組成物
WO1999031256A2 (en) * 1997-12-18 1999-06-24 Immunex Corporation Cathepsin dc proteins, dna encoding the proteins, and their use in human cancer prognosis
JP2003510079A (ja) * 1999-09-30 2003-03-18 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナトリウムチャンネルβ１Ａサブユニットに関連する方法および組成物

Also Published As

Publication number Publication date
DE60224002T2 (de) 2008-11-06
EP1336847B1 (de) 2007-12-12
ES2296834T3 (es) 2008-05-01
DE60224002D1 (de) 2008-01-24
EP1336847A1 (de) 2003-08-20

Similar Documents

Publication Publication Date Title
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
HUP0300299A2 (hu) Szabad aminosavakat tartalmazó kompozíció
EP1302542A4 (de) Neues, physiologisch aktives peptid und dessen verwendung
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
HUP0301179A2 (hu) Módosított VIII-as faktor
ATE427116T1 (de) Behandlung von bakteriellen infektionen
BR0316502A (pt) Compostos quìmicos
ATE411035T1 (de) Caseinhydrolysat, verfahren zur dessen herstellung sowie dessen verwendung
ATE370968T1 (de) Varianten des menschliche koagulationsfaktors vii
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
DE60306505D1 (de) Verfahren zur behandlung von brustdrüsenerkrankungen
DE60218843D1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
ATE344262T1 (de) 2-heteroarylcarbonsäureamide
ATE245439T1 (de) Inhibitoren für homöostase und immunfunktion
ATE395602T1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
ATE381017T1 (de) Kathepsin y inhibitoren für die entwicklung von medikamenten zur schmerzbehandlung
ATE363923T1 (de) Verwendung von flumazenil zur herstellung eines medikaments für die behandlung von kokainabhängigkeit
ATE166656T1 (de) Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen
DE602004004754D1 (de) Peptizusammensetzung für die Mundhöhle
NO20052525D0 (no) Spleisevariant av humant hypofyseveksthormon
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
ATE374593T1 (de) Methode zur haarbehandlung gekennzeichnet durch applikation bestimmter 2-hydroxyalkansäuren
BR0307039A (pt) Compostos, em particular de derivados uréias ou ésteres do ácido haloacetamidobenzóico e sua utilização para o tratamento de doenças parasitárias
ATE397753T1 (de) Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung
ATE439136T1 (de) Verfahren zur behandlung von halitose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties